Why Mankind (MNKD) Stock Is Up Today

NEW YORK (TheStreet) -- Mankind (MNKD) shares are up 3.3% to $10.11 on Friday after analysts at RBC Capital initiated coverage with an "outperform" rating and $16 price target on the company.

The price target represents a 60% upside over the company's opening price today.

Must ReadWarren Buffett's 25 Favorite Stocks 

With the rapid action insulin market currently valued at over $16 billion, the optimistic outlook rests on the shoulders of the company's potential breakthrough insulin inhaler Afrezza

The company's stock price fell yesterday however after it announced that an Afrezza partnership may not happen until 6-8 weeks after the drugs approval.

M Chart

M data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind